CytomX Therapeutics, Inc. (CTMX) Form 8-K — Jun 22, 2026
CytomX Therapeutics stockholders approved an amendment to the company's Certificate of Incorporation to double the authorized number of common shares from 300 million to 600 million. The Certificate of Amendment was filed with the Delaware Secretary of State on June 22, 2026, following approval at the Annual Meeting on June 17, 2026. In addition to the charter amendment, stockholders approved increases to the company's equity compensation plans. The 2015 Equity Incentive Plan was amended to authorize an additional 6.5 million shares, and the Employee Stock Purchase Plan was increased by 1 million shares.
Key figures
- Shares Outstanding
- 217702919
- Shares voted
- 183604084
- Espp increase
- 1000000
- Votes for directors
- 182976052
- Abstentions directors
- 245351
- Votes against directors
- 382681
- Authorized preferred shares
- 10000000
- Equity incentive plan increase
- 6500000
- Authorized common shares pre amendment
- 300000000
- Authorized common shares post amendment
- 600000000
Price after filing
Close on the filing date to close N calendar days later (from $3.04). Historical, not a forecast.
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.